Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2021. október 7., csütörtök 09:00 |
Debiopharm & Dexa Medica launch triptorelin collaboration to bring new hope to women with endometriosis (part 1) |
|
Lausanne, Switzerland - Tangerang, Indonesia, 7 October, 2021 (APA/OTS) - Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the Indonesian launch of triptorelin for the treatment of women with gynecological disorders, particularly endometriosis. Triptorelin, marketed under the brand name Pamorelin® is one of the most common gonadotropin-releasing hormone agonists (GnRH-a) used worldwide to help women with endometriosis reduce pain-related symptoms by inducing a low estrogen status. Clinical research revealed pain symptom improvement with Pamorelin® as being confirmed by the reduction in the volume of endometriotic nodules during treatment vs. placebo.(1) |
Endometriosis is a chronic, debilitating disease involving long-term
inflammation and the presence of functional endometrial glands and
stroma outside the uterine cavity. Having serious consequences for
general and reproductive health, pelvic endometriosis has a high
incidence estimated between 10% of reproductive aged women worldwide
(approximately 190 million) and remains underdiagnosed.(2)
Furthermore, up to 49% of women reporting chronic pelvic pain are
known to suffer from endometriosis.(2) Dexa Medica's nation-wide
launch and distribution of triptorelin, as Debiopharm's exclusive
Indonesian licensee, will help patients in the region gain access to
the pain-relieving benefits of hormone suppression with Pamorelin®.
"We naturally recognized that Dexa Medica was the ideal company to
pioneer triptorelin access to patients in Indonesia. Their high
standards of ethics, regional pharmaceutical leadership, and strong
commercialization track record and reputation align well with
Debiopharm's values," stated Fabrice Paradies, Senior Director,
Business Development & Global Commercial Alliances, Debiopharm.
"This alliance with Dexa Medica is highly valued as they are
dedicated to covering Indonesia, with over 270 million people the
largest country in Southeast Asia, having the capability to manage
the logistic complexity to provide treatment access to patients in a
country having a population of over 270 million on nearly 1,000
inhabited islands." "Medical management of endometriosis primarily aims to delay
disease progression and alleviate symptoms. Aside from infertility,
the most debilitating symptoms in women with endometriosis are pain
manifested as severe dysmenorrhea, dyspareunia, chronic pelvic pain,
dysuria or dyschezia. These symptoms also tend to worsen with
repeated menstrual cycles," stated Raymond R. Tjandrawinata, Ph.D.,
Director of Business and Scientific Development PT Dexa Medica.
"We, as a leading pharmaceutical company in Indonesia, are very
proud and excited to collaborate with a globally reputed company,
Debiopharm, to market quality products such as Triptorelin which
helps Indonesians to overcome health problems related to
endometriosis. Although there is currently no definitive data, the
general prevalence is around 3% - 10%, especially in women of
reproductive age in Indonesia," stated Commercial Director PT Dexa
Medica, V Hery Sutanto.
About Pamorelin®
Pamorelin® (triptorelin) is an agonist analogue of the natural
gonadotropin-releasing hormone (GnRH), the only agonist of its kind
that differs from natural GnRH by a single amino acid and works by
decreasing the amount of certain hormones in the body. Pamorelin®
helps women to maintain estradiol suppression, an important factor
in the management and relief of chronic pain associated with
endometriosis. When the basic activation process of the GnRH
receptor is interrupted, this initiates a cascade of events leading
to the fall in pituitary luteinizing hormone (LH) and follicle
stimulating hormone (FSH) secretion, causing a low production of
circulating estradiol and progesterone. Manufactured by Debiopharm
in Switzerland, this long-acting formulation is marketed and
distributed globally through regional licensees.
About Dexa Medica
PT Dexa Medica (member of Dexa Group) is a leading Indonesian
research-based pharmaceutical company, which was established on
September 27th, 1969. Starting with the export of pharmaceutical
products created by Indonesian scientists in 1993, now Dexa Medica
has exported pharmaceutical products to 4 continents: Africa,
America, Asia and Europe. Regarding the export of pharmaceutical
products, Dexa Medica has become a pioneer in Indonesian
pharmaceutical manufacturers entering the UK and was awarded the
Primaniyarta Award from the Indonesian government in 2017, 2018, and
2019. (continues)
|
|
|
|
|
|
|
2021. október 7., csütörtök 09:00 |
Debiopharm & Dexa Medica launch triptorelin collaboration to bring new hope to women with endometriosis (part 2) |
|
Lausanne, Switzerland - Tangerang, Indonesia, 7 October, 2021 (APA/OTS) - |
Debiopharm's commitment to patients Debiopharm aims to develop & manufacture innovative therapies that
target high unmet medical needs in oncology and infectious diseases.
Bridging the gap between disruptive discovery products and
real-world patient reach, we identify high-potential compounds and
technologies for in-licensing, clinically demonstrate their safety
and efficacy and then select large pharmaceutical commercialization
partners to maximize patient access globally. For more information, please visit www.debiopharm.com We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews
Debiopharm Contact Dawn Haughton Communication Manager dawn.bonine@debiopharm.com Tel: +41 (0)21 321 01 11
Dexa Medica Contact Sonny Himawan Head of Corporate Communications soni.himawan@dexagroup.com
References:
(1.) Maggiore ULR et al. Expert Opin Pharmacother 2014
Jun;15(8):1153-79.
(2.) Zondervan K et al. N Engl J Med 2020;382:1244-1256
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|